Methazolamide 25 mg for Glaucoma, Open-Angle

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Sue Anschutz-Rodgers Eye Center, Aurora, CO
Glaucoma, Open-Angle+1 More
Methazolamide 25 MG - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether methazolamide can safely and effectively lower intraocular pressure. This trial will use methazolamide 25 mg to treat glaucoma, open-angle. There will be no placebo group.

Eligible Conditions

  • Glaucoma, Open-Angle

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

3 Primary · 5 Secondary · Reporting Duration: Day 1 (Pre-dosing, then 4- and 8- hours post dosing), Day 7 (Pre-dosing, then 4- and 8- hours post dosing), Day 14 (Pre-dosing, then 4- and 8- hours post dosing)

Day 14
Number of treatment emergent adverse events
Day 14
Change in Urine electrolytes
Day 14
Change in Plasma levels of electrolytes
Change in Plasma levels of methazolamide
Day 14
Percent IOP change at each follow-up Visit
Percent IOP lowering at each follow-up Visit
Significant change in Intraocular Pressure from Baseline
Day 14
Change in Urinary pH

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Methazolamide 25 mg
1 of 2
Methazolamide 50 mg
1 of 2
Active Control

30 Total Participants · 2 Treatment Groups

Primary Treatment: Methazolamide 25 mg · No Placebo Group · Phase 4

Methazolamide 25 mg
Drug
ActiveComparator Group · 1 Intervention: Methazolamide 25 MG · Intervention Types: Drug
Methazolamide 50 mg
Drug
ActiveComparator Group · 1 Intervention: Methazolamide 50 MG · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 1 (pre-dosing, then 4- and 8- hours post dosing), day 7 (pre-dosing, then 4- and 8- hours post dosing), day 14 (pre-dosing, then 4- and 8- hours post dosing)
Closest Location: Sue Anschutz-Rodgers Eye Center · Aurora, CO
Photo of aurora 1Photo of aurora 2Photo of aurora 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Glaucoma, Open-Angle
0 CompletedClinical Trials

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,557 Previous Clinical Trials
1,911,914 Total Patients Enrolled
7 Trials studying Glaucoma, Open-Angle
478 Patients Enrolled for Glaucoma, Open-Angle
Malik Y. Kahook, MDPrincipal InvestigatorUniversity of Colorado, Denver
6 Previous Clinical Trials
175 Total Patients Enrolled
1 Trials studying Glaucoma, Open-Angle
31 Patients Enrolled for Glaucoma, Open-Angle

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between 50 and 90 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.